Abstract
The report covers forecast and analysis for the myelofibrosis treatment market on the global and regional level. The study provides historic data for 2016 and 2017 along with a forecast from 2018 to 2024 based on revenue (USD Million). The study includes drivers and restraints for the myelofibrosis treatment market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the myelofibrosis treatment market on a global level.
In order to give the users of this report a comprehensive view of the myelofibrosis treatment market, we have included competitive landscape and analysis of Porter’s Five Forces Model for the market. The study encompasses a market attractiveness analysis, where diagnosis type, treatment type, drug type, and end users segments are benchmarked based on their market size, growth rate, and general attractiveness.
The report provides company market share analysis in order to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including merger and acquisitions, new drug launch, drug pipeline, agreements, partnerships, collaborations & joint ventures, R&D, and regional expansion of major participants involved in the market on the global and regional basis. Moreover, the study covers price trends analysis, the product portfolio of various companies according to the region.
The study provides a decisive view of the myelofibrosis treatment market by segmenting the market into diagnosis type, treatment type, drug type, end users, and regions. All the segments have been analyzed based on present and the future trends and the market is estimated from 2018 to 2024. Based on diagnosis type, the market is segmented into gene mutation analysis, bone marrow biopsy, an imaging test, and blood tests. Based on treatment type, the market is segmented into chemotherapy, blood transfusions, stem cell transplant, splenectomy, radiation therapy, and others. Based on drug type, the market is segmented into hydroxyurea, immunomodulators, JAK inhibitor, and others. Based on end users, the market is segmented into hospitals, clinics, and bone marrow transplant centers. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa with its further categorization into major countries including the U.S., Canada, Germany, the UK, France, Spain, Italy, China, Japan, India, Brazil, and Mexico. This segmentation includes demand for myelofibrosis treatment based on individual diagnosis type, treatment type, drug type, and end users in all the regions and countries.
The report also includes detailed profiles of end players such as Eli Lilly and Company, Gilead Sciences Inc., F. Hoffmann-La Roche Ltd., Incyte Corporation, Merck & Co., Bristol-Myers Squibb Company, Novartis AG, Amgen Inc., and Celgene Corporation, among others.
The report segments the global myelofibrosis treatment market as follows:
Global Myelofibrosis Treatment Market: Diagnosis Type Segment Analysis
Gene Mutation Analysis
Bone Marrow Biopsy
Imaging Test
Blood Test
Global Myelofibrosis Treatment Market: Treatment Type Segment Analysis
Chemotherapy
Blood Transfusions
Stem Cell Transplant
Splenectomy
Radiation Therapy
Others
Global Myelofibrosis Treatment Market: Drug Type Segment Analysis
Hydroxyurea
Immunomodulators
JAK Inhibitors
Others
Global Myelofibrosis Treatment Market: End-User Segment Analysis
Hospitals
Clinics
Bone Marrow Transplant Centers
Global Myelofibrosis Treatment Market: Regional Segment Analysis
North America
The U.S.
Europe
UK
France
Germany
Asia Pacific
China
Japan
India
Latin America
Brazil
Middle East and Africa